|
Orthologous residues
|
|
XIAP (human): S87‑p, XIAP (mouse): S87‑p, XIAP (rat): S87‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
[32P] bio-synthetic labeling, mutation of modification site, phospho-antibody, western blotting
|
|
Disease tissue studied:
ovarian cancer
|
|
Relevant cell lines - cell types - tissues:
293 (epithelial), A2780 (ovarian), COS (fibroblast)
|
|
Cellular systems studied:
cell lines
|
|
Species studied:
human, monkey
|
|
Enzymes shown to modify site in vitro:
|
|
|
|
Upstream Regulation
|
|
Potential in vivo enzymes for site:
|
|
Type
|
Enzyme
|
Evidence
|
Notes
|
|
KINASE
|
Akt1 (human)
|
transfection of constitutively active enzyme, modification site within consensus motif, co-immunoprecipitation, pharmacological inhibitor of upstream enzyme, phospho-motif antibody, pharmacological activator of upstream enzyme
|
|
|
KINASE
|
Akt2 (human)
|
transfection of constitutively active enzyme, modification site within consensus motif, co-immunoprecipitation, pharmacological inhibitor of upstream enzyme, phospho-motif antibody, pharmacological activator of upstream enzyme
|
|
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
insulin
|
|
|
|
increase
|
|
|
LY294002
|
insulin
|
|
|
inhibit treatment-induced increase
|
|
|
|
Downstream Regulation
|
|
Effect of modification (function):
protein stabilization
|
|
Effect of modification (process):
apoptosis, inhibited
|
